Rucaparib
clovis
['gyn', 'ariel4', 'rucaparib', 'ovarian', 'brca', 'optima']
results of the phase 3 ariel4 trial comparing rucaparib vs chemotherapy for patients with relapsed ovarian cancer and deleterious brca1/2 mutations raised questions about optimal sequencing of parp inhibitors in this setting. #gyncsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.